Infiltrating macrophages in diabetic nephropathy promote podocytes apoptosis via TNF-α-ROS-p38MAPK pathway

Yinfeng Guo1, Zhixia Song1, Min Zhou1

  • 1Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009, China.

Oncotarget
|September 9, 2017
PubMed

Insights

High glucose activates macrophages, leading to increased podocyte apoptosis in diabetic nephropathy (DN) via TNF-α, ROS, and p38MAPK. Blocking these pathways may treat DN.

Area of Science:

  • Nephrology
  • Immunology
  • Cell Biology

Background:

  • Macrophage infiltration is implicated in diabetic nephropathy (DN) pathogenesis.
  • The specific role of infiltrating macrophages in podocyte apoptosis within DN remains unclear.
  • Previous studies show macrophages induce apoptosis in various cells, but not specifically podocytes.

Purpose of the Study:

  • To investigate the contribution of macrophages to podocyte apoptosis in diabetic nephropathy (DN).
  • To elucidate the mechanisms by which macrophages influence podocyte apoptosis under high glucose conditions.

Main Methods:

  • In vivo study using streptozotocin (STZ)-induced diabetic rats to assess podocyte apoptosis and macrophage infiltration.
  • In vitro transwell co-culture system to examine macrophage-podocyte interactions under normal and high glucose conditions.
  • Analysis of macrophage polarization (M1), conditioned media effects, reactive oxygen species (ROS) production, p38MAPK activation, and the role of tumor necrosis factor-alpha (TNF-α).

Main Results:

  • Diabetic rats showed increased podocyte apoptosis and kidney macrophage infiltration.
  • High glucose-activated M1 macrophages exacerbated podocyte apoptosis in co-culture, dependent on ROS and p38MAPK signaling.
  • Tumor necrosis factor-alpha (TNF-α) was identified as a key mediator, with its blockade inhibiting macrophage-induced podocyte apoptosis.

Conclusions:

  • High glucose-activated macrophages promote podocyte apoptosis in DN through a TNF-α-dependent pathway involving ROS and p38MAPK.
  • Targeting TNF-α secretion from activated macrophages and the ROS-p38MAPK pathway presents potential therapeutic strategies for DN.